Ph.D., Senior Vice President, DPU Head, ln Silico Discovery, GSK Pharmaceuticals
John Baldoni heads a newly formed drug discovery unit dedicated to explore and apply in silico methodology to drug discovery and development at GSK. This new appointment follows his role as Senior Vice President, Platform Technology and Science (PTS), GSK Pharma R&D. Baldoni joined GSK in 1989 and has worked in the pharmaceutical industry for 37 years. His experience spans new chemical entity design, development and commercialization, and biopharmaceutical development. In progressing to his current role, Baldoni has held various positions at GSK including Senior Vice President, Preclinical Development; Vice President, Product Development; Director, Product Development; and Assistant Director, Biopharmaceutical Formulation Development, among others. He has led several key cross-functional problem solving and strategic initiatives. Baldoni has a BS in biochemistry (1974), and MS and Ph.D. degrees in chemistry (1980) from Penn State University.
Session Abstract – PMWC 2018 Silicon Valley
Session Synopsis: AI has the potential to expedite the clinical drug discovery and development process by applying sophisticated algorithms to the analysis and mining of different data sources to predict molecule behavior and suitability as drug targets or therapeutic entities. This session will cover different approaches and AI platforms, and how they will impact the pharmaceutical industry and specifically, the drug discovery and development processes.